MARKET

VERA

VERA

Vera Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.32
-0.43
-3.13%
After Hours: 13.32 0 0.00% 16:04 06/28 EDT
OPEN
13.92
PREV CLOSE
13.75
HIGH
13.92
LOW
13.02
VOLUME
66.90K
TURNOVER
0
52 WEEK HIGH
37.11
52 WEEK LOW
12.29
MARKET CAP
360.68M
P/E (TTM)
-6.5438
1D
5D
1M
3M
1Y
5Y
Insider Buying: The Vera Therapeutics, Inc. (NASDAQ:VERA) Chief Financial Officer Just Bought 329% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Vera Therapeutics, Inc. ( NASDAQ:VERA ) Chief...
Simply Wall St. · 06/18 12:20
BRIEF-Vera Therapeutics Says Interim Data From Phase 2 Trial Showed Mau868 Was Well Tolerated In Kidney Transplant Recipients With Bk Viremia
reuters.com · 06/04 18:40
Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients
MAU868, a first-in-class monoclonal antibody, was well tolerated in kidney transplant recipients with BK viremiaData presented as oral late breaker at American Transplant Congress BK Virus is a leading cause of transplant loss and transplant-associated mor...
GlobeNewswire · 06/04 18:30
BRIEF-Vera Therapeutics Inc Files For Mixed Shelf Of Up To $400 Million
reuters.com · 06/03 20:16
Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today annou...
GlobeNewswire · 06/02 11:30
Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data In Two Oral Presentations At The 59th European Renal Association Congress
Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress Atacicept is the first known investigational therapy to decrease both
Benzinga · 05/20 20:06
Vera Therapeutics GAAP EPS of -$0.71 misses by $0.07
Vera Therapeutics press release (NASDAQ:VERA): Q1 GAAP EPS of -$0.71 misses by $0.07. Vera reported approximately $151 million in cash, cash equivalents and marketable securities as of March 31, 2022
Seekingalpha · 05/16 13:47
Vera Therapeutics: Q1 Earnings Insights
  Vera Therapeutics (NASDAQ:VERA) reported its Q1 earnings results on Monday, May 16, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/16 12:28
More
No Data
Learn about the latest financial forecast of VERA. Analyze the recent business situations of Vera Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VERA stock price target is 42.67 with a high estimate of 89.00 and a low estimate of 30.00.
High89.00
Average42.67
Low30.00
Current 13.00
EPS
Actual
Estimate
-0.63-0.47-0.32-0.16
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 49
Institutional Holdings: 20.71M
% Owned: 76.50%
Shares Outstanding: 27.08M
TypeInstitutionsShares
Increased
23
2.93M
New
14
3.26M
Decreased
7
132.17K
Sold Out
2
29.84K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.05%
Pharmaceuticals & Medical Research
+0.60%
Key Executives
Non-Executive Chairman/Independent Director
Kurt von Emster
President/Chief Executive Officer/Founder/Director
Marshall Fordyce
Chief Financial Officer
Sean Grant
Senior Vice President - Finance/Chief Accounting Officer
Joseph Young
Senior Vice President
Tom Doan
Senior Vice President
Tad Thomas
Other
Joanne Curley
Other
Lauren Frenz
Other
Celia Lin
Independent Director
Andrew Cheng
Independent Director
Patrick Enright
Independent Director
Kimball Hall
Independent Director
Maha Katabi
Independent Director
Scott Morrison
Independent Director
Beth Seidenberg
No Data
No Data
About VERA
Vera Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a biologic inhibitor of B cells and plasma cells. Atacicept is self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. It is also developing MAU868, a monoclonal antibody that neutralizes infection with BK Virus.

Webull offers kinds of Vera Therapeutics Inc stock information, including NASDAQ:VERA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VERA stock methods without spending real money on the virtual paper trading platform.